CANbridge Pharmaceuticals lands $43m Series E
China and Boston-based CANbridge Pharmaceuticals Inc, a developer of drugs to treat rare diseases and targeted cancers, has raised $43 million in Series E financing.
China and Boston-based CANbridge Pharmaceuticals Inc, a developer of drugs to treat rare diseases and targeted cancers, has raised $43 million in Series E financing.
Copyright PEI Media
Not for publication, email or dissemination